{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:15:30Z","timestamp":1790615730063,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007037","name":"Ministeriet Sundhed Forebyggelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007037","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpsychires.2026.07.013","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:25:56Z","timestamp":1784355956000},"page":"601-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Guided tapering of antipsychotics in patients with Schizophrenia: Relapse-status and cognition"],"prefix":"10.1016","volume":"201","author":[{"given":"A.","family":"N\u00f8stdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0780-7099","authenticated-orcid":false,"given":"M.\u00d8.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-2944","authenticated-orcid":false,"given":"B.","family":"Fagerlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-7028","authenticated-orcid":false,"given":"J.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3647-9709","authenticated-orcid":false,"given":"C.K.","family":"Lemvigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2026.07.013_bib1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1017\/S0033291718001836","article-title":"Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial","volume":"49","author":"Albert","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-023-02501-7","article-title":"Effects of risperidone\/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial","volume":"13","author":"Allott","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0920-9964(03)00189-0","article-title":"A new instrument for measuring insight: the beck cognitive insight scale","volume":"68","author":"Beck","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000081413","article-title":"Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Source","volume":"11","author":"Berman","year":"2005","journal-title":"Eur. Addctn. Res."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-023-02718-6","article-title":"The magnitude and variability of neurocognitive performance in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies","author":"Catalan","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamapsychiatry.2024.2890","article-title":"Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis","volume":"82","author":"Feber","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib7","first-page":"1306","article-title":"Sustained remission in drug-free schizophrenic patients","author":"Fenton","year":"1987","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/NMD.0000000000000997","article-title":"WAIS-IV performance in patients with schizophrenia","volume":"207","author":"Fuentes-Dur\u00e1","year":"2019","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.779607","article-title":"Anticholinergic burden and cognitive performance in patients with schizophrenia: a systematic literature review","author":"Georgiou","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/npp.2009.211","article-title":"Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies","volume":"35","author":"Goldberg","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.14074su1c.02","article-title":"Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia","volume":"77","author":"Green","year":"2016","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-023-04552-y","article-title":"Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia","volume":"23","author":"Haddad","year":"2023","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib13","article-title":"The discrepancy between subjective and objective evaluations of cognitive and functional ability among people with schizophrenia: a systematic review","author":"Harris","year":"2024","journal-title":"Behav. Sci."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib14","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1017\/S0033291712000220","article-title":"Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study","volume":"42","author":"Harrow","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","article-title":"Anticholinergic medication burden\u2013associated cognitive impairment in schizophrenia","volume":"178","author":"Joshi","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","article-title":"Schizophrenia is a cognitive illness: time for a change in focus","volume":"70","author":"Kahn","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1017\/S0033291718001393","article-title":"Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: a meta-analysis","volume":"49","author":"Kishi","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jamapsychiatry.2024.0016","article-title":"Cognitive function and variability in antipsychotic drug-naive patients with first-episode psychosis: a systematic review and meta-analysis","volume":"81","author":"Lee","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib23","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib25","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291725101591","article-title":"Successful antipsychotic dose tapering leading to better cognition in patients with remitted psychosis: results of guided antipsychotic reduction to reach minimum effective dose (GARMED) trial","volume":"55","author":"Liu","year":"2025","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib26","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1073191113478153","article-title":"WAIS-IV profile of cognition in schizophrenia","volume":"20","author":"Michel","year":"2013","journal-title":"Assessment"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-024-05699-y","article-title":"Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia\u2013 a case series","volume":"24","author":"M\u00f8lgaard","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.834333","article-title":"Differential effects of aripiprazole and amisulpride on negative and cognitive symptoms in patients with first-episode psychoses","volume":"13","author":"Nielsen","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib30","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291724001910","article-title":"Deprescribing antipsychotics in patients with schizophrenia: findings from a specialized clinic","author":"N\u00f8stdal","year":"2024","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1176\/appi.ps.20230641","article-title":"Motivations for and experiences with antipsychotic tapering among patients with schizophrenia seeking guided dose reduction","volume":"75","author":"N\u00f8stdal","year":"2024","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib32","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1017\/S0033291721004153","article-title":"Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis","volume":"53","author":"Oomen","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10608-018-9963-0","article-title":"Establishing clinical cutoff values for the beck cognitive insight scale","volume":"43","author":"Penney","year":"2019","journal-title":"Cognit. Ther. Res."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.31887\/DCNS.2019.21.3\/trobbins","article-title":"Pharmacological treatment of cognitive deficits in nondementing mental health disorders","volume":"21","author":"Robbins","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib35","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/10497323231195821","article-title":"Mental health staff's perspectives on tapering of antipsychotic medication: a focus group study","volume":"33","author":"Roed","year":"2023","journal-title":"Qual. Health Res."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/schbul\/sbi017","article-title":"Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes","volume":"31","author":"Rosen","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol Consumption-II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114383","article-title":"Effect of antipsychotic dose reduction on cognitive function in schizophrenia","volume":"308","author":"Singh","year":"2022","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jpsychires.2026.07.013_bib39","article-title":"Early dose reduction or discontinuation vs maintenance antipsychotics after first psychotic episode remission","author":"Sommer","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib40","article-title":"European psychiatric association guidance on assessment of cognitive impairment in schizophrenia","volume":"65","author":"Vita","year":"2022","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib41","series-title":"Wechsler Adult Intelligence Scale--Fourth Edition","author":"Wechsler","year":"2008"},{"key":"10.1016\/j.jpsychires.2026.07.013_bib42","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626003778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626003778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:27:50Z","timestamp":1790612870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395626003778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S0022395626003778"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.07.013","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guided tapering of antipsychotics in patients with Schizophrenia: Relapse-status and cognition","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}